Sarcopenia is an important public health problem as it relates to physical frailty, mobility limitation, and even premature death.
1Although the importance of age-related loss of muscle mass and function (ie, sarcopenia) has been known for decades, sarcopenia still does not have a universally agreed clinical definition and diagnostic criteria. Therefore, its reported prevalence ranges between 10% and 40% depending on the assessment techniques, diagnostic criteria, and characteristics of the populations.
- Reginster J.Y.
- Cooper C.
- Rizzoli R.
- et al.
Recommendations for the conduct of clinical trials for drugs to treat or prevent sarcopenia.
Aging Clin Exp Res. 2016; 28: 47-58
- Mayhew A.J.
- Amog K.
- Phillips S.
- et al.
The prevalence of sarcopenia in community-dwelling older adults, an exploration of differences between studies and within definitions: A systematic review and meta-analyses.
Age Ageing. 2019; 48: 48-56
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Journal of the American Medical Directors Association
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Recommendations for the conduct of clinical trials for drugs to treat or prevent sarcopenia.Aging Clin Exp Res. 2016; 28: 47-58
- The prevalence of sarcopenia in community-dwelling older adults, an exploration of differences between studies and within definitions: A systematic review and meta-analyses.Age Ageing. 2019; 48: 48-56
- Age-related changes in skeletal muscle mass among community-dwelling Japanese: A 12-year longitudinal study.Geriatr Gerontol Int. 2014; 14: 85-92
- Cumulative and incremental value of sarcopenia components on predicting adverse outcomes.J Am Med Dir Assoc. 2020; 21: 1481-1489.e3
- Putative cut-points in sarcopenia components and incident adverse health outcomes: An SDOC Analysis.J Am Geriatr Soc. 2020; 68: 1429-1437
- Bilateral anterior thigh thickness: A new diagnostic tool for the identification of low muscle mass?.J Am Med Dir Assoc. 2019; 20: 1247-1253.e2
- Association of muscle strength and gait speed with cross-sectional muscle area determined by mid-thigh computed tomography—A comparison with skeletal muscle mass measured by dual-energy x-ray absorptiometry.J Frailty Aging. 2020; 9: 82-89
- STAR—Sonographic thigh adjustment ratio. A golden formula for the diagnosis of sarcopenia.Am J Phys Med Rehabil. 2020; 99: 902-908
- Corporate Priorities: A Continuing Study of the New Demands on Business.Yankelovich Inc, Stanford, CT1972
- The role of DXA bone density scans in the diagnosis and treatment of osteoporosis.Postgrad Med J. 2007; 83: 509-517
Published online: March 08, 2021
© 2021 AMDA - The Society for Post-Acute and Long-Term Care Medicine.